Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kovax Flu Tetra PF
- Development stage
- Unknown
- Lead developer
- Koreavaccine
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Kovax Flu Tetra PF is a quadrivalent, inactivated split-virion influenza vaccine developed and manufactured by Koreavaccine. It is designed to provide active immunization against four strains of the influenza virus: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The "PF" designation indicates that the vaccine is supplied in a pre-filled syringe, which is intended to facilitate ease of administration and ensure dosage accuracy. As a split-virion vaccine, it contains disrupted viral particles that expose key antigens, primarily hemagglutinin, to the immune system to stimulate a protective immune response. It is indicated for the prevention of influenza caused by the specific strains included in the formulation and is typically administered via intramuscular injection.
- Brand names
- Kovax Flu Tetra PFKovax Flu Tetra PF Inj.
- Other names
- Kovax Flu Tetra
02
Targets
HA0 (Influenza B virus hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on Kovax Flu Tetra PF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kovax Flu Tetra PF.